Therapeutic targeting of NF-κB in myelodysplastic syndromes and acute myeloid leukaemia the biological heterogeneity

Expert Opinion on Therapeutic Targets

Volumn 14, Issue 11, 2010, Pages 1139-1142

  Bruserud, Øystein ^a,b   Reikvam, Håkon ^a  

^a UNIVERSITY OF BERGEN   (Norway)

^b HAUKELAND UNIVERSITY HOSPITAL   (Norway)

Author keywords

[No Author keywords available]

Indexed keywords

4 (2 AMINOETHYLAMINO) 1,8 DIMETHYLIMIDAZO[1,2 A]QUINOXALINE; BORTEZOMIB; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; PEP 005; PROTEASOME INHIBITOR; PROTEIN KINASE C INHIBITOR; UNCLASSIFIED DRUG;

ACUTE GRANULOCYTIC LEUKEMIA; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; CELL COMMUNICATION; CELL CYCLE PROGRESSION; CELL PROLIFERATION; DRUG TARGETING; HUMAN; LEUKEMIA CELL; MYELODYSPLASTIC SYNDROME; PROTEIN TARGETING; PROTEINASE INHIBITION; REVIEW; SIGNAL TRANSDUCTION;

ANIMALS; ANTINEOPLASTIC AGENTS; DRUG DESIGN; HUMANS; LEUKEMIA, MYELOID, ACUTE; MOLECULAR TARGETED THERAPY; MYELODYSPLASTIC SYNDROMES; NF-KAPPA B; PROTEASE INHIBITORS; SIGNAL TRANSDUCTION;

EID: 77958057784     PISSN: 14728222     EISSN: None     Source Type: Journal    
DOI: 10.1517/14728222.2010.525021     Document Type: Review

References (18)

1. Lowenberg B. Acute myeloid leukaemia: the challenge of capturing disease variety. Hematol Am Soc Hematol Educ Program 2008:1-11
2. Jansen JH, Langemeijer SMC. The biological basis of myelodysplastic syndrome. Hematology Education: the education program for the annual congress of the European Hematology Association 2010;4:163-170
3. Breccia M, Alimena G. NF-kB as a potential therapeutic target in myelodysplastic syndromes and acute myeloid leukaemia. Expert Opin Ther Targets 2010;14(11):1157-1176
4. Lapidot T, Sirard C, Vormoor J, et al. A cell initiating human acute myeloid leukaemia after transplantation into SCID mice. Nature 1994;367(6464):645-648
5. Nimer SD. MDS: a stem cell disorder - but what exactly is wrong with the primitive hematopoietic cells in this disease? Hematol Am Soc Hematol Educ Program 2008:43-51
6. Reikvam H, Olsnes AM, Gjertsen BT, et al. Nuclear factor-kappaB signaling: a contributor in leukemogenesis and a target for pharmacological intervention in human acute myelogenous leukaemia. Crit Rev Oncog 2009;15(1-2):1-41
7. Bruserud O, Gjertsen BT, Foss B, Huang TS. New strategies in the treatment of acute myelogenous leukaemia (AML): in vitro culture of aml cells - the present use in experimental studies and the possible importance for future therapeutic approaches. Stem Cells 2001;19(1):1-11
8. Bruserud O, Ryningen A, Olsnes AM, et al. Subclassification of patients with acute myelogenous leukaemia based on chemokine responsiveness and constitutive chemokine release by their leukemic cells. Haematologica 2007;92(3):332-341
9. Olsnes AM, Ersvaer E, Ryningen A, et al. The protein kinase C agonist PEP005 increases NF-kappaB expression, induces differentiation and increases constitutive chemokine release by primary acute myeloid leukaemia cells. Br J Haematol 2009;145(6):761-774
10. Ersvaer E, Kittang AO, Hampson P, et al. The protein kinase C agonist PEP005 (ingenol 3-angelate) in the treatment of human cancer: A balance between efficacy and toxicity. Toxins 2010;2(1):174-194
11. Roodman GD. Novel targets for myeloma bone disease. Expert Opin Ther Targets 2008;12(11):1377-1387
12. Stapnes C, Doskeland AP, Hatfield K, et al. The proteasome inhibitors bortezomib and PR-171 have antiproliferative and proapoptotic effects on primary human acute myeloid leukaemia cells. Br J Haematol 2007;136(6):814-828
13. Stapnes C, Gjertsen BT, Reikvam H, Bruserud O. Targeted therapy in acute myeloid leukaemia: current status and future directions. Expert Opin Investig Drugs 2009;18(4):433-455
14. Guzman ML, Rossi RM, Karnischky L, et al. The sesquiterpene lactone parthenolide induces apoptosis of human acute myelogenous leukaemia stem and progenitor cells. Blood 2005;105(11):4163-4169
15. Nilsson B, Nilsson O, Ahlman H. Treatment of gastrointestinal stromal tumours: imatinib, sunitinib - and then? Expert Opin Investig Drugs 2009;18(4):457-468
16. Hatfield KJ, Olsnes AM, Gjertsen BT, Bruserud O. Antiangiogenic therapy in acute myelogenous leukaemia: targeting of vascular endothelial growth factor and interleukin 8 as possible antileukemic strategies. Curr Cancer Drug Targets 2005;5(4):229-248
17. Dimberg A. Chemokines in Angiogenesis. Curr Top Microbiol Immunol 2010. [Epub ahead of print]
18. Reikvam H, Hatfield KJ, Lassalle P, et al. Targeting the angiopoietin (Ang)/Tie-2 pathway in the crosstalk between acute myeloid leukaemia and endothelial cells: studies of Tie-2 blocking antibodies, exogenous Ang-2 and inhibition of constitutive agonistic Ang-1 release. Expert Opin Investig Drugs 2010;19(2):169-183